Profile data is unavailable for this security.

About the company

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

  • Revenue in GBP (TTM)17.79bn
  • Net income in GBP1.91bn
  • Incorporated1992
  • Employees64.40k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lonza Group AG4.41bn521.18m19.93bn15.38k37.563.92--4.428.767.4874.1784.000.39942.847.31360,455.304.754.925.716.1737.7734.4611.899.880.951327.430.392438.8221.869.11-1.3649.7422.206.67
Novo Nordisk A/S13.58bn4.56bn76.65bn42.45k21.4416.8614.905.5515.8815.8847.3220.,676,041.0037.6338.3273.1670.1184.1084.3733.5633.080.655527.080.083649.390.12096.001.318.9327.7712.61
GlaxoSmithKline plc31.26bn4.03bn78.97bn95.49k19.5719.4311.362.530.80960.78456.280.81540.52751.724.94327,364.107.427.5813.7112.5168.7568.4414.0714.490.484312.050.904110.872.103.0643.60-
AstraZeneca plc17.79bn1.91bn81.53bn64.40k41.459.5217.174.611.511.5114.046.570.36041.424.17276,308.303.693.895.425.3979.9481.1310.259.910.58063.140.6421145.38-1.67-3.06-9.64-3.36-7.80-0.3937
Sanofi SA32.20bn3.94bn85.01bn104.23k21.47--15.132.623.543.5328.99--------347,936.20--4.15--4.9068.2768.3511.0512.14--25.63--89.44-1.502.6614.473.498.651.86
Data as of Jun 20 2019. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX

Institutional shareholders

23.76%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 31 Dec 201854.59m4.16%
BlackRock Investment Management (UK) Ltd.as of 31 Dec 201844.72m3.41%
Wellington Management Co. LLPas of 01 May 201941.67m3.18%
The Vanguard Group, Inc.as of 01 May 201936.92m2.82%
Legal & General Investment Management Ltd.as of 01 May 201929.01m2.21%
Norges Bank Investment Managementas of 01 May 201928.31m2.16%
BlackRock Fund Advisorsas of 01 May 201922.27m1.70%
Fidelity Management & Research Co.as of 01 May 201921.07m1.61%
Dodge & Coxas of 01 May 201917.35m1.32%
BlackRock Advisors (UK) Ltd.as of 01 May 201915.73m1.20%
More ▼
Data from 31 Dec 2018 - 31 Mar 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.